NEXIGN
22.7.2020 03:02:09 CEST | Business Wire | Press release
Nexign (part of ICS Holding), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider for telecommunications service providers, today announced that it expands its international presence to Latin America by opening a new office in Santo Domingo, Dominican Republic. This initiative will enable Nexign to strengthen its positions in emerging markets by offering LATAM customers solutions to drive digital transformation efforts.
According to the GSMA report , the data traffic in LATAM will grow more than sixfold by 2024. Also, GSMA expects the mobile penetration rate to reach 73% by 2025. Nexign aims to use its 28 years of engineering excellence to help local telecom operators consolidate their systems and provide customers with better connectivity, uninterrupted internet access and other services. The office in Dominican Republic will focus on business development initiatives for the entire LATAM and providing operators with modular, truly convergent solutions to enable stress-free modernization and sustainable performance.
“During the past three years, Nexign has grown significantly. As a maturing company we are taking the next step in our international expansion strategy and establishing our corporate presence in Latin America. We believe that understanding of the local market specifics is critical for smooth digital transformation of local CSPs. We will leverage our market knowledge and industry expertise to support operators in the region and speed up the modernization process for them. With Nexign’s BSS solutions, they will be able to meet local customer demands and bring added value to business,” said Igor Gorkov, CEO at Nexign.
“LATAM is an emerging market with great potential. Operators in the region realize that they need up-to-date BSS solutions to keep up with customer needs. As a result, they are ready to embrace new development opportunities and find new ways to monetize traffic. We are happy to support local operators and offer them solutions that can enable them achieve their business goals and deliver superior services to subscribers,” said Andrey Moldovan, Regional Director, LATAM.
Learn more about Nexign’s international footprint here: https://nexign.com/en/contact-us
Nexign , a part of Intellectual Computer Systems Holding (ICS Holding) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering value-driven, high-performance product solutions since 1992. As communications service providers become digital service providers, Nexign accelerates their transformation through engineering excellence and agile products and services that facilitate revenue-stream diversification. For more than 28 years, the company has delivered on its promise of unlocking value in the short-term while ensuring customers’ investments support long-term growth.
Headquartered in St. Petersburg, Nexign employs 1,800 people in offices through Russia, the Commonwealth of Independent States, the Middle East, Africa and Southeast Asia. The company has delivered more than 120 projects across 16 countries.
For more information, please visit the website and follow the latest news from Nexign on Twitter , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200721005775/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom